Head to Head Review: Nabriva Therapeutics (NASDAQ:NBRV) & scPharmaceuticals (NASDAQ:SCPH)

scPharmaceuticals (NASDAQ:SCPH) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and valuation.

Risk and Volatility

scPharmaceuticals has a beta of 0.12, meaning that its share price is 88% less volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500.

Profitability

This table compares scPharmaceuticals and Nabriva Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
scPharmaceuticals	-327.29%	-132.39%	-58.71%
Nabriva Therapeutics	-148.11%	-365.53%	-135.81%

Insider and Institutional Ownership

89.5% of scPharmaceuticals shares are owned by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are owned by institutional investors. 5.5% of scPharmaceuticals shares are owned by insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings for scPharmaceuticals and Nabriva Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
scPharmaceuticals	0	0	2	0	3.00
Nabriva Therapeutics	0	0	0	0	N/A

scPharmaceuticals presently has a consensus target price of $19.00, indicating a potential upside of 351.31%.

Earnings & Valuation

This table compares scPharmaceuticals and Nabriva Therapeutics’ revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
scPharmaceuticals	$13.59 million	11.17	-$54.81 million	($1.48)	-2.84
Nabriva Therapeutics	$35.59 million	0.00	-$57.19 million	($19.20)	N/A

scPharmaceuticals has higher earnings, but lower revenue than Nabriva Therapeutics. scPharmaceuticals is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

scPharmaceuticals beats Nabriva Therapeutics on 7 of the 11 factors compared between the two stocks.

About scPharmaceuticals

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

About Nabriva Therapeutics

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.